skip to main content

MS – Ofatumumab — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

HardMultiple Sclerosis & CNS InflammationMS – OfatumumabSCE Neurology

A patient with relapsing multiple sclerosis is commencing ofatumumab. Which schedule correctly describes the loading phase and first maintenance dose?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — 20 mg subcutaneously at weeks 0, 1 and 2, then monthly beginning at week 4

Ofatumumab for relapsing multiple sclerosis is self-administered as 20 mg subcutaneously at weeks 0, 1 and 2; there is no week-3 injection, and monthly maintenance begins at week 4. The intravenous six-monthly schedule describes ocrelizumab rather than ofatumumab. The other schedules are not authorised regimens.

Reference: Kesimpta Summary of Product Characteristics: https://www.medicines.org.uk/emc/product/12433/smpc